What Discoveric Bio Group does

Discoveric Bio Group is a privately held, Switzerland-domiciled biotechnology holding company (Pfäffikon) that develops fully human bi- and multi-specific antibody therapeutics. The group operates through three wholly-owned subsidiaries — discoveric bio alpha (Alzheimer's Disease), discoveric bio beta (Antimicrobial Resistance), and discoveric bio gamma (Neuroinflammation) — and runs a pipeline of six drug candidates (NIDB-3101/3102/3103 for AD/PD, NIDB-3001/3002 for Gram-negative infections, and NIDB-3601 for neuroinflammation).

Its core technology is the κλ body platform licensed from Light Chain Bioscience (NovImmune SA), which produces bispecific antibodies consisting of two identical heavy chains and two different light chains (one kappa, one lambda). This format retains the natural human IgG architecture, which the company argues reduces immunogenicity and anti-drug antibody risk relative to engineered bispecific formats. Discovery is augmented by an AI/ML partnership with Innoplexus that processes hundreds of terabytes of structured and unstructured life science data for knowledge retrieval and process automation.

The business model is pre-commercial: the company is R&D-stage with no approved products, no disclosed revenue, no pricing, and no distribution channels. The intended go-to-market path implied by the "Partner with us" infrastructure and the holding-subsidiary structure is partnership-, licensing-, or co-development-based monetization with pharmaceutical companies rather than direct commercialization. Capital is founder-controlled, with no institutional investors or parent company disclosed in available sources.

Name

Discoveric Bio Group

Legal name

discoveric bio group

Website

https://discovericbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Discoveric Bio Group is a Swiss biotech holding company developing fully human bi- and multi-specific antibody therapeutics for Alzheimer's Disease, Antimicrobial Resistance, and Neuroinflammation using the κλ body platform from Light Chain Bioscience, operating pre-commercially through three wholly-owned subsidiaries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Bispecific antibody therapeutics
• Alzheimer's disease treatment
• Antimicrobial resistance therapies
• Neuroinflammation therapeutics
• Biopharmaceutical R&D

Headquarters

HQ city

Pfaffikon

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Marketing channels2 records

Core offering

Discoveric Bio Group is a pre-commercial biotech developing a portfolio of fully human bi- and multi-specific antibody therapeutics targeting Alzheimer's Disease, Antimicrobial Resistance (Gram-negative bacterial infections), and Neuroinflammation. The group operates through three subsidiaries (discoveric bio alpha, beta, gamma) and leverages the proprietary κλ body bispecific antibody platform licensed from Light Chain Bioscience, combined with AI/ML-powered drug discovery through its partnership with Innoplexus.

Product overview

Discoveric Bio Group is a biotech company developing a portfolio of fully human bi- and multi-specific antibody therapeutics through its three subsidiaries: discoveric bio alpha (Alzheimer's disease), discoveric bio beta (antimicrobial resistance), and discoveric bio gamma (neuroinflammation). The company leverages the proprietary κλ body platform from LightChain Bioscience, which produces truly natural bispecific antibodies using kappa and lambda light chains. The pipeline includes six therapeutic programs: NIDB-3101/3102/3103 for Alzheimer's and Parkinson's diseases, NIDB-3001/3002 for Gram-negative bacterial infections, and NIDB-3601 for neuroinflammation.

Differentiator

Problem solved

Functional benefit

Products and services

• NIDB-3101 A κλ body (bispecific antibody) drug candidate for Alzheimer's Disease. Candidate has been selected and is in non-clinical development phase. Intended for patients suffering from Alzheimer's Disease.
• NIDB-3102 A bispecific antibody drug candidate targeting Alzheimer's Disease and Parkinson's Disease. Clinical candidate selection expected Q3/2025.
• NIDB-3103 A bispecific antibody drug candidate for Parkinson's Disease. Currently in discovery phase.
• NIDB-3001 A fully human κλ IgG antibody targeting Gram-negative outer membrane proteins for the treatment of Gram-negative bloodstream infections. Interferes with essential Gram-negative outer membrane processes, inhibiting bacterial growth independent of host effector functions.
• NIDB-3002 A fully human κλ IgG antibody targeting Gram-negative outer membrane proteins for the treatment of Gram-negative lung infections. Interferes with essential Gram-negative outer membrane processes, inhibiting bacterial growth independent of host effector functions.
• NIDB-3601 A therapeutic antibody targeting neuroinflammation for neurodegenerative diseases. Currently in target identification phase.

Quantifiable outcome

• Fully human κλ antibodies minimize immunogenicity and loss of exposure risk compared to non-human or engineered formats
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• InnoplexuscoreTechnology or IntegrationStrategic partnership with Innoplexus, a leading global AI-based platform for drug discovery and development. Innoplexus provides solutions that generate real-time insights from hundreds of terabytes of structured and unstructured life science data, facilitating virtual drug discovery with continuous, objective and informed decision-making at unprecedented speed.
• Light Chain Bioscience (NovImmune SA)coreTechnology or IntegrationPartnership for the κλ body antibody platform technology. Light Chain Bioscience has developed highly competitive and advantageous antibody platform using human antibody light chains. The κλ bodies consist of two identical heavy chains and two different light chains (one kappa and one lambda), creating bispecific antibodies that fully retain the sequence and architecture of human antibodies.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Numab Therapeutics: Swiss biotech engineering multi-specific antibody therapeutics using a proprietary λ-cap and other formats. Most relevant geographic and technological peer; multi-specific platform company with oncology and inflammation focus.
• Genmab: Pioneer in bispecific antibody engineering (DuoBody platform) developing therapeutics across oncology and infectious disease. Closest comparable platform peer to Discoveric's κλ body bispecific technology and pipeline model.
• Zymeworks: Developer of multispecific antibody platforms (Azymetric, EFFECT) with therapeutic programs in oncology and inflammation. Directly comparable as a multispecific/bispecific engineering platform company advancing internal and partnered assets.
• MacroGenics: Built the DART bispecific antibody platform and multiple Trispecific programs in oncology. Comparable in deploying proprietary bispecific scaffolds across internal pipeline assets.
• Xencor: Engineers Fc and bispecific antibodies (XmAb platforms) and pursues internal and partnered programs across immunology and oncology. Direct platform-comparable peer in bispecific/multispecific antibody design.

Broad incumbents

• Argenx: Late-stage antibody developer with multiple approved assets (e.g., efgartigimod) and a pipeline spanning autoimmune and neurological indications. Comparable antibody therapeutics developer; broader commercial scale than Discoveric.

Others

• Innoplexus: AI-based drug discovery platform company partnered with Discoveric for AI/ML-driven candidate identification. Enabling technology partner rather than direct competitor; included to flag the relationship ecosystem.
• Light Chain Bioscience / NovImmune SA: Originating developer of the κλ body bispecific antibody platform that Discoveric licenses. Technology licensor and platform progenitor; relevant as the upstream platform provider rather than direct competitor.

Emerging players

• AC Immune: Swiss clinical-stage biopharmaceutical company developing antibody and small-molecule therapeutics for Alzheimer's and other neurodegenerative diseases. Closest indication-overlap peer for Discoveric bio alpha and gamma.
• Prothena: Clinical-stage developer of antibody-based therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable therapeutic-area focus on AD/PD antibody therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/discoveric-bio-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Discoveric Bio Group